Hong Sun

Ionis Pharmaceuticals (United States)

Papers

1

Total Citations

350

H-Index

1

About

Hong Sun has made foundational contributions to the field of antisense therapeutics, with a primary focus on understanding the molecular mechanisms that enable DNA-like drugs to silence target genes. Her landmark 2004 study, which has garnered over 350 citations, provided definitive proof that human RNase H1 is the critical enzyme responsible for the degradation of target RNA induced by antisense oligonucleotides. This work resolved a long-standing question in the field and directly shaped the rational design of more effective therapeutic agents. Beyond this key discovery, Sun’s research has advanced our knowledge of how RNase H1 activity can be harnessed for pharmacological benefit, bridging fundamental biochemistry with clinical application. Her findings have had a lasting impact on the development of nucleic-acid-based drugs, influencing both academic research and pharmaceutical pipelines. For students and researchers interested in RNA biology, drug discovery, or the translational power of basic enzymology, Hong Sun’s work stands as a model of how mechanistic insight can drive therapeutic innovation.

Research Focus

Key Achievements

1
H-Index
1
Papers
350
Total Citations
350
Avg Citations/Paper
🏆 Most Cited Paper
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
350 citations · 2004
📈 Most Prolific Year: 2004 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Ionis Pharmaceuticals (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago